Files

669654.pdf (112.02 KB)

Document type

Article

Version

Published version

Publication date

2017-01-13

Publication license

cc-by-nc (c) Ampudia-Blasco, Francisco Javier, 2017
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/108575

Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.2147/IJGM.S115566

Abstract

The recently published cardiovascular outcomes data for the first sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower rates of death from cardiovascular causes or from any causes and lower hospitalization rates from heart failure compared with placebo, both in addition to standard care. This commentary discusses the existence of a possible class effect considering the available evidence described for other SGLT2 inhibitors.

Subject

Malalties cardiovasculars, Diabetis, Glucosa

Subject (English)

Cardiovascular diseases, Diabetes, Glucose

Citation

Collections

Articles publicats en revistes (Medicina)

Citation

AMPUDIA-BLASCO, Francisco Javier, et al. Following the results of the EMPA-REG OUTCOME trial with Empagliflozin, is it possible to speak of a class effect?. International Journal of General Medicine. 2017. Vol. 10, num. 23-26. ISSN 1178-7074. [consulted: 14 of June of 2026]. Available at: https://hdl.handle.net/2445/108575

Export metadata

JSON - METS

Share record